Off-the-shelf cancer vaccines might offer cancer type-specific treatment options, which can be administered very quickly compared to personalized approaches, thus quenching the tumor before it can progress. However, the development of effective therapeutic vaccines has been hampered by their weak immunogenicity and off-target responses. Thus far, only one cancer vaccine has been approved for use in humans, namely, sipuleucel-T for treatment of prostate cancer.
In this Collection we are accepting articles that address:
-
Epitope-specific cancer vaccines
-
Identification of tumor-associated epitopes for vaccine development
-
Adjuvants and delivery systems
-
Preclinical models
-
Clinical trials and related issues
